Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Greenwich LifeSciences, Inc. - Common stock (NQ:GLSI)

9.420 +0.080 (+0.86%)
Streaming Delayed Price Updated: 3:37 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Greenwich LifeSciences, Inc. - Common stock

< Previous 1 2 3 4 Next >
62 Biggest Movers From Yesterday
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 42.8% to close at $3.07 on Thursday following the company's recent uplisting to the Nasdaq.... 
Via Benzinga
Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
From Greenwich LifeSciences, Inc.
Via Business Wire
3 Stocks Insiders Are Buying on Market Turbulence
When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely. 
Via InvestorPlace
65 Biggest Movers From Yesterday
Gainers Exterran Corporation (NYSE: EXTN) shares surged 59.7% to close at $4.79 on Monday after the company said it would merge with Enerflex to create a premier integrated... 
Via Benzinga
Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings
Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a standard course of... 
Via Benzinga
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
From Greenwich LifeSciences, Inc.
Via Business Wire
58 Biggest Movers From Friday
Gainers Hagerty, Inc. (NYSE: HGTY) shares jumped 46.5% to close at $15.62. TuanChe Limited (NASDAQ: TC) gained 44.7% to settle at $3.30. IO Biotech, Inc. (NASDAQ: IOBT) shares... 
Via Benzinga
Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
From Greenwich LifeSciences, Inc.
Via Business Wire
The Moonshot Investor: The Insider Track Strategy
Excerpts of this article were originally published on October 4 and 18, 2021, as part of Tom Yeung's Moonshot Investor series. Investors interested in 
Via InvestorPlace
3 Stocks Insiders Are Snapping Up. Do They Know Something We Don’t?
Insider trading is heavily regulated, but it still happens, and it's worth paying attention to big moves from insiders for potential profits. 
Via InvestorPlace
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Set to Join Russell 2000® Index
From Greenwich LifeSciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021
Upgrades For Chatham Lodging Trust (NYSE: 
Via Benzinga
Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer Recurrence
Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have... 
Via Benzinga
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
From Greenwich LifeSciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.